ANI Pharmaceuticals Q1 revenue rose 43.4% to $197.12 million, EPS beat consensus, and 2025 guidance was raised on strong Cortrophin Gel and generics growth.
Cortrophin Demand Is Soaring For ANI Pharma, CEO Says Well-Positioned To Mitigate Potential Tariff Impact
